Get the Stockscreener App
8.81
1.01%
-0.09
Pre-market:
8.80
-0.010
-0.11%
Eyepoint Pharmaceuticals Inc stock is traded at $8.81, with a volume of 812.34K.
It is down -1.01% in the last 24 hours and up +43.72% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$8.90
Open:
$9.35
24h Volume:
812.34K
Relative Volume:
0.99
Market Cap:
$633.76M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-4.8407
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
-4.34%
1M Performance:
+43.72%
6M Performance:
+9.85%
1Y Performance:
-2.22%
1-Day Range:
$8.78
$9.595
1-Week Range:
$8.50
$9.595
52-Week Range:
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
8.81 | 633.76M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals - Benzinga
RBC Capital Initiates Coverage on EyePoint Pharmaceuticals (EYPT - GuruFocus
EyePoint Pharmaceuticals (EYPT) Poised for Success with Positive Outlook | EYPT Stock News - GuruFocus
RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target - marketscreener.com
After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st
EyePoint (EYPT) Grants Stock Options to New Employees as Inducement | EYPT Stock News - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 563 - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals
EyePoint Awards 12,500 Shares in Stock Options to Three New Hires at $9.03 Per Share - Stock Titan
(EYPT) Trading Report - news.stocktradersdaily.com
EyePoint Stock: Retaining My 'Risky Buy' CallPivotal Data Due Early 2026 (NASDAQ:EYPT) - Seeking Alpha
Cantor Fitzgerald Weighs in on EYPT FY2026 Earnings - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint at Goldman Sachs Healthcare Conference: Sustained-Release Vision By Investing.com - Investing.com Canada
Breakout Momentum Plays You May Not Know About - Investing.com
Squarepoint Ops LLC Has $302,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Ameriprise Financial Inc. Grows Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Nuveen Asset Management LLC Raises Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
ProShare Advisors LLC Buys 8,981 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
(EYPT) Investment Report - news.stocktradersdaily.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $276,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
Millennium Management LLC Buys New Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint advances with Duravyu Phase III trial - Yahoo
H.C. Wainwright maintains Buy on EyePoint with $22 target - Investing.com India
H.C. Wainwright maintains Buy on EyePoint with $22 target By Investing.com - Investing.com Nigeria
EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders are up 29% this past week, but still in the red over the last year - simplywall.st
EyePoint Pharmaceuticals’ (EYPT) Buy Rating Reaffirmed at HC Wainwright - Defense World
Biggest Companies on Nasdaq EyePoint Pharmaceuticals Insights by Kalkine - Kalkine Media
Analyst Expectations For EyePoint Pharmaceuticals's Future - Benzinga
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 P - GuruFocus
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 Price Target | EYPT Stock News - GuruFocus
Bank of America Corp DE Acquires 145,065 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint Secures Triple Conference Spotlight: Goldman Sachs, Jefferies, and Guggenheim Healthcare Events - Stock Titan
EyePoint completes enrollment for phase 3 LUGANO trial of DURAVYU in wet AMD - Ophthalmology Times
EyePoint at Stifel Forum: Strategic Advances in Ophthalmology By Investing.com - Investing.com Canada
JPMorgan maintains EyePoint stock Overweight with $26 target - Investing.com India
JPMorgan maintains EyePoint stock Overweight with $26 target By Investing.com - Investing.com UK
Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration - marketscreener.com
EyePoint (EYPT) Surpasses Enrollment Goal in Key Phase 3 Trial | - GuruFocus
EyePoint Completes Enrollment for DURAVYU Phase 3 Trial - TipRanks
EyePoint Pharmaceuticals Reports Rapid Enrollment Progress in Phase 3 LUGANO Trial of DURAVYU™ for Wet AMD Treatment - Nasdaq
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration - The Manila Times
Clinical Trial Milestone: EyePoint's Revolutionary 6-Month Eye Treatment Completes Phase 3 Enrollment - Stock Titan
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Globe and Mail
Deutsche Bank AG Has $1.59 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
BNP Paribas Financial Markets Purchases New Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
(EYPT) Trading Signals - news.stocktradersdaily.com
Northern Trust Corp Has $4.79 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Insider Buying: Karen Zaderej Acquires Additional Shares of EyeP - GuruFocus
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):